InflaRx NV of Germany has raised a net $57.1 million from a primary and secondary offering of its shares on Nasdaq to support its portfolio of drugs for inflammatory diseases that target the complement system, a component of the innate immune system.
Takeda Pharmaceutical Company Ltd has won the agreement of Shire Plc to a takeover that values the Ireland-based company at $62 billion and will potentially strengthen Takeda’s position in the US. Although headquartered in Dublin, Shire generates most of its business from the US.
The UK gene therapy company Autolus Ltd has filed papers with the US Securities and Exchange Commission for a proposed initial public offering of its shares on Nasdaq. The offering will take the form of American Depositary Shares each representing one ordinary share in the company.
The UK cancer vaccine company Scancell Holdings Plc has raised £8.7 million from existing and new shareholders in order to advance its portfolio of early clinical stage vaccines for melanoma, non-small cell lung cancer and other solid tumours.
Fresh from a successful initial public share offering (IPO) on Nasdaq, MorphoSys AG is progressing plans for the potential commercialisation in the US of its first wholly-owned product – an antibody therapeutic for aggressive lymphoma.
Novartis has received a new cancer indication for its chimeric antigen receptor T (CAR-T) cell therapy Kymriah (tisagenlecleucel) enabling the gene therapy to be administered to a broader group of patients. The new indication is for large B cell lymphoma, including diffuse large B cell lymphoma (DLBCL).
e-Therapeutics Plc aims to identify intervention strategies for the potential treatment of Parkinson’s disease under a new collaboration with the drug discovery company C4X Discovery Holdings Plc.
Crescendo Biologics Ltd has secured $70 million in a Series B financing round to advance its lead product into the clinic for a cancer indication and further develop its pipeline of biologics that are based on a variable domain of the human antibody.
The Wellcome Trust has awarded £4.3 million to PredictImmune of Cambridge UK to finance a clinical trial of the company’s prognostic biomarker test for Crohn’s disease. The assay was developed by researchers at the University of Cambridge.
Faced with declining sales for its diabetes products, Sanofi SA shifted course in the first quarter to strengthen its specialty pharmaceutical business by acquiring the haemophilia product developer Bioverativ Inc and the antibody company Ablynx NV.